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Rhinovirus 3C protease suppresses
apoptosis and triggers caspase-
independent cell death
Mark Lötzerich1,2, Pascal S. Roulin1, Karin Boucke1, Robert Witte1, Oleg Georgiev1 and Urs F. Greber 1
Abstract
Apoptosis and programmed necrosis (necroptosis) determine cell fate, and antagonize infection. Execution of these
complementary death pathways involves the formation of receptor-interacting protein kinase 1 (RIPK1) containing
complexes. RIPK1 binds to adaptor proteins, such as TRIF (Toll-IL-1 receptor-domain-containing-adaptor-inducing
interferon-beta factor), FADD (Fas-associated-protein with death domain), NEMO (NF-κB regulatory subunit IKKγ),
SQSTM1 (sequestosome 1/p62), or RIPK3 (receptor-interacting protein kinase 3), which are involved in RNA sensing,
NF-κB signaling, autophagosome formation, apoptosis, and necroptosis. We report that a range of rhinoviruses impair
apoptosis and necroptosis in epithelial cells late in infection. Unlike the double-strand (ds) RNA mimetic poly I:C
(polyinosinic:polycytidylic acid), the exposure of dsRNA to toll-like receptor 3 (TLR3) in rhinovirus-infected cells did not
lead to apoptosis execution. Accordingly, necroptosis and the production of ROS (reactive oxygen species) were not
observed late in infection, when RIPK3 was absent. Instead, a virus-induced alternative necrotic cell death pathway
proceeded, which led to membrane rupture, indicated by propidium iodide staining. The impairment of dsRNA-
induced apoptosis late in infection was controlled by the viral 3C-protease (3Cpro), which disrupted RIPK1-TRIF/FADD
/SQSTM1 immune-complexes. 3Cpro and 3C precursors were found to coimmuno-precipitate with RIPK1, cleaving the
RIPK1 death-domain, and generating N-terminal RIPK1 fragments. The depletion of RIPK1 or chemical inhibition of its
kinase at the N-terminus did not interfere with virus progeny formation or cell fate. The data show that rhinoviruses
suppress apoptosis and necroptosis, and release progeny by an alternative cell death pathway, which is controlled by
viral proteases modifying innate immune complexes.
Introduction
Apoptosis and necroptosis control the fate of selected
cells during development of multicellular organisms. They
are distinct hallmarks of host defense against pathogens,
and tune the immunological tolerogenic or immunogenic
responses1–4. Cells dying by apoptosis condense chro-
matin and disperse into membrane-wrapped fragments,
whereas necrotic cells release their contents and elicit
innate immune responses from immune and non-
immune cells. Apoptosis requires proteolysis by cas-
pases, and phenotypically involves blebbing of the plasma
membrane, and nuclear DNA fragmentation without cell
lysis5,6. Necrosis does not require caspases, and leads to
cell swelling, membrane rupture, and leakage of cyto-
plasm1. Programmed necrosis is known as necroptosis,
and has important roles in development. Apoptosis and
necroptosis can be triggered by activation of Toll-like
receptors (TLR), or virus infection4,7.
RNA viruses can set off cell death through DNA
damage or production of double-strand RNA (dsRNA),
activation of TLR3, retinoic acid inducible gene I (RIG-I)-
like receptors (RLR), protein kinase R (PKR), or indirectly
through extrinsic pathways, such as tumor necrosis factor
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receptor (TNFR) signaling. They antagonize cell death
pathways by dedicated proteins, and thereby tune the
production and release of virions from infected cells8–10.
Picornaviruses, such as poliovirus (PV), coxsackievirus
(CV) or encephalomyocarditis virus (EMCV) are thought
to induce apoptosis but also to inhibit apotosis execu-
tion8,11–17. In addition, picornavirus infection may inter-
fere with innate immunity related IFN-signaling17–20.
Mechanisms of cell death of rhinovirus (RV)-infected
cells are unknown. Human RVs (HRVs) belong to the
Enterovirus genus of the Picornaviridae. They are the
causative agents of the common cold, triggering mild
symptoms in many individuals. In individuals with
asthma, chronic obstructive pulmonary disease or cystic
ﬁbrosis HRV infections have severe and often life-
threatening complications21. This is associated with
altered integrity of respiratory epithelia, and innate and
adaptive immune responses22. HRV trigger innate
immunity reactions upon replication on cytoplasmic
tubulo-vesicular membranes of epithelial cells in the
upper respiratory tract, due to danger signals, such as viral
dsRNA intermediates23–25. Danger signals from enter-
oviruses are decoded by TLR3 and the RNA helicase
MDA5 (melanoma differentiation-associated gene 5),
which trigger an innate anti-viral response26–28. Such
response can lead to apoptosis and eliminate infected cells
without largely affecting integrity of upper respiratory
tracts16,22. At exacerbated conditions, lower respiratory
tract infections are more destructive due to induction of
unknown immune-stimulatory cell death pathways21.
Enteroviruses target TLR3, MDA5 and the transducers
TRIF (Toll-IL-1 receptor-domain-containing-adaptor-
inducing interferon-beta factor) and MAVS (mitochon-
drial antiviral signaling protein) by their proteases 2A and
3C, or indirectly by caspase activation, and attenuate pro-
inﬂammatory cytokine and type I interferon produc-
tion2,18,29,30. TLR3-signaling is not only associated to
proinﬂammatory cytokine response but also to apoptotic-
and necroptotic cell death. In epithelial cells viral dsRNA
signaling involving TLR3 induces caspase-8-mediated
apoptosis that depends on RIPK1 and TRIF. Receptor-
interacting serine/threonine-protein kinase 1 (RIPK1) is
highly conserved in vertebrates and essential for orga-
nismic homeostasis31–33. It forms signaling complexes
controlling execution of apoptosis or necroptosis2,4,7,34–36.
Its N-terminal kinase domain is important for necroptotic
cell death. The intermediate domain recruits adaptor
proteins including p62/SQSTM1, and NEMO (NF-kappa
B essential modulator), for regulation of cell death,
autophagy, and inﬂammation37. The RIP-homotypic
interaction motif (RHIM) binds to the TLR3/TLR4
adaptor TRIF and RIPK3. The C-terminal death domain
(DD) enables interactions with death receptors TNFR1,
Fas, TRAIL-R1/R2 and adaptors, such as FADD (Fas-
associated protein with DD) or TRADD (TNF-receptor-
associated death domain). The absence of caspase activity
redirects extrinsic death pathways from apoptosis towards
necroptosis7,33,38. Here we investigated how rhinoviruses
target RIPK1 to toggle-switch between apoptosis and
necroptosis, and control cell death pathways.
Results
HRV infection induces necrosis rather than apoptosis in
primary cells and cell cultures
Human primary airway epithelial cells of nasal origin
(hAECN), or HeLa cells, were infected with a panel of
human rhinoviruses, HRV-A1A, A2, A16, B14, B37, and
coxsackie virus B3 (CVB3) (Figs. 1a, 2). At an MOI of 1 all
of these infections gave rise to virus-speciﬁc double strand
(ds) RNA as early as 5–7 h post infection (pi), indicative of
initial stages of viral replication23,24,39. HRV-A16 infection
phenotypes were then analyzed by electron microscopy,
and indicated necrotic features at 15 h pi, including
rounding up, vacuolated cytoplasm, a convoluted nuclear
envelope (white arrow heads), apparent plasma mem-
brane bursts (black arrow heads), and alterations of the
mitochondrial architecture, including swelling of the
cristae without apparent membrane bursting (arrows,
Figs. 1b, 2a). These phenotypes were distinct from apop-
totic features induced by puromycin or the synthetic
dsRNA mimetic poly I:C (poly-ribo-inosinic: poly-ribo-
cytidylic acid) that induced the formation of apoptotic
bodies (Fig. 2a). The results with puromycin and poly I:C
were in agreement with previous reports40,41.
The absence of apoptotic features was reinforced by
the observation that HRV-A16-infected HeLa cells
showed no signs of inter-nucleosomal cleavage of DNA
by nucleases into multiples of 180 bp fragments, unlike
puromycin-treated cells (Fig. 2b). Infected cells showed
no signs of unspeciﬁc DNA processing, indicative of
necrotic cell death nor reactive oxygen species (ROS),
and no reduction in metabolic activity, except very late
in infection (Figs. 1c, d; 2a−d). Poly I:C and puromycin
treatment of hAECN and HeLa cells generated a strong
annexin V signal indicating apoptosis. In contrast,
infected cells became only slightly annexin V-positive
late in infection (Figs. 1d, 2e). Poly I:C or puromycin-
induced apoptosis was inhibited by pan-caspase inhibi-
tors QVD or zVADfmk but not by the necroptosis
inhibitor necrostatin 1 (NEC-1) or 3Cpro inhibitor
AG7088 (Supplementary Figure S1A−B). Puromycin
treatment of hAECN cells induced another hallmark of
apoptosis, the cleavage of lamin A/C, which could be
inhibited by addition of the pan-caspase inhibitor Q-
VD-OPH (QVD, Fig. 1e). HRV-A16 infection led to
distinct lamin A/C cleavage at late time points, inde-
pendent of QVD, suggesting caspase-independent clea-
vage (Fig. 1e). Notably, the inhibition of apoptosis by the
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Fig. 1 Necrotic cell death rather than apoptosis in HRV-A16-infected primary human nasal epithelial cells. a Dose-dependent infection of
hAECN with various A- and B-type rhinoviruses (HRV-A16, HRV-B14, HRV-B37, HRV-A2, HRV-A1A), and CVB3 and correlation with cell number. Values
are means ± SD, n = 3. b Electron micrographs of hAECN infected with HRV-A16 (MOI 1) or treated with poly I:C or puromycin for 15 h, or uninfected
cells. Proximity of vesicular structures with the cell surface indicated by black arrowheads, and swollen mitochondrial cristae in infected cells
highlighted by arrows. c ROS production of HRV-A16 or HRV-A1A (MOI 1) infected cells 24 h pi, compared to luprox- (100 μM, 1 h) or menadione (100
μM, 1 h)-treated cells. d FACS analysis of annexin V stainings of hAECN infected with HRV-A16 or HRV-A1A (MOI 1) for 4, 8, 15 or 24 h and comparison
with poly I:C-treated cells. Values are means from approximately 10,000 cells analyzed ± SD, n = 3. e Western blots against lamin A/C and beta-tubulin
from lysates of hAECN cells infected with HRV-A16 (MOI 1, 15 h) or treated with puromycin (5 µg/ml, 15 h) with or without pan-caspase inhibitor QVD
(5 µM). Mr denotes relative molecular weight in kDa. f FACS analysis propidium iodide (PI) stainings of hAECN infected with HRV-A16 or HRV-A1A (MOI
1) for 4, 8, 15 or 24 h and comparison with poly I:C-treated cells. Values are means from approximately 10,000 cells analyzed ± SD, n = 3. g Western
blot analysis of caspase 3, 7, 8, 9 activations in hAECN after infection with HRV-A16 (MOI 1, 15 h), poly I:C transfection (5 μg/ml) or external poly I:C
addition (ext, 50 μg/ml). Arrow highlights virus-induced caspase-7 processing product; undeﬁned antibody background is indicated by a star.
Infection is indicated by blotting against 3Cpro using beta-tubulin as a loading control.
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pan-apoptosis inhibitor zVADfmk did not affect the
growth of HRV-A16 (Fig. 2f).
Signiﬁcantly, the HRV-A1A or A16-infected hAECN or
HeLa cells became strongly positive for propidium iodide
(PI), unlike poly I:C-treated cells, indicating the loss of
plasma membrane integrity at 15 h pi (Figs. 1f, 2g). Pur-
omycin- or poly I:C-induced cell leakage was enhanced by
QVD and z-VADfmk, and not affected by NEC-1 or
AG7088 (Rupintrivir)42, validating the speciﬁcity of the
assay systems (Supplementary Figure S1C−D). Enzymatic
Fig. 2 (See legend on next page.)
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FLICA caspase-8/9 assays showed low levels of activation
of initiator caspases at 15 or 24 h pi, but robust levels in
puromycin-treated cells (Fig. 2h, and Supplementary
Figure S2). This was conﬁrmed by western blotting for
cleaved caspase-8 (Supplementary Figure S1E). The
treatment of hAECN or HeLa cells with poly I:C gener-
ated a procaspase-8 cleavage product p30 (Figs. 1g, 2i),
which had been described to conduct an alternative
pathway of apoptosis43. It also stimulated intrinsic apop-
tosis, as indicated by the p37 processing product of
procaspase-9. In contrast, no active p30 and very little p37
fragments were detectable in HRV-A16-infected cells
(Figs. 1g, 2i). The caspase-8/9 activations were validated
by enzymatic activity assays using caspase-8/9 inhibitors
z-IETDfmk and z-LEHDfmk (Supplementary Fig. S2A
−B). In accordance, we found no activation of caspase-3/7
or cleavage of PARP in HRV-A16-infected cells, whereas
puromycin or poly I:C treatment led to activation of the
effector caspases-3/7 (p17 and p20 fragments), and clea-
vage of the caspase substrate Poly-ADP-ribose poly-
merase (PARP) (see 89 kDa fragment in Figs. 1g, 2i,k).
Interestingly, caspase-7 was cleaved to a p34 fragment
in the infected cells, insensitive to QVD, unlike in
puromycin-treated cells (Figs. 1g, 2k). The appearance of
p34 was, however, inhibited by AG7088, suggesting that
caspase-7 is a substrate for proteases of infected cells
(Fig. 2k).
Taken together, the data suggest that although dsRNA
is abundantly produced during HRV-A16 infection, and
although apoptosis is induced in HeLa or hAECN cells by
synthetic dsRNA, no signs of apoptosis execution were
evident in the infected cells. Yet, late in infection (24 h pi),
the cells displayed necrotic rather than apoptotic features.
Virus growth and release were insensitive to pan-caspase
inhibitors.
Rhinovirus infection suppresses the pro-apoptotic TLR3
pathway
The dsRNA mimic poly I:C induces extrinsic and
intrinsic apoptotic pathways through TLR3, MDA5, or
PKR44. This was not affected by siRNA-mediated knock-
down of MDA5 or FADD, unlike the knockdown of TLR3
and/or the TLR3 adaptor TRIF, which suppressed the
activation of caspase-8, caspase-3, and caspase-7 (Fig. 3a
−f). RIPK1 controls death signaling, and associates with
TLR3, MDA5-MAVS, and PKR complexes to transmit
dsRNA PAMP (pathogen-associated molecular pattern)
signals reviewed in ref. 45. Knockdown of RIPK1 effec-
tively suppressed activation of caspase-8 in poly I:C-
treated cells (Fig. 3c, e). In contrast, HRV-A16-infected
cells positive for dsRNA did not execute apoptosis.
Fluorescence microscopy and immuno-gold cryo-sections
revealed that a fraction of TLR3 localized to rhinovirus-
induced dsRNA at large vesicular structures (Fig. 4a, b).
The signal was speciﬁc since no TLR3 signal was observed
in cells treated with TLR3-siRNAs (Fig. 3f). The dsRNA-
positive structures also contained RIPK1, as demonstrated
by single section confocal ﬂuorescence microscopy in
hAECN and HeLa cells (Fig. 4c, d). However, TLR3 or
RIPK1 knockdown had essentially no effect on virus
protein production (Fig. 3d, e). These results suggest that
although dsRNAs might be accessed by TLR3 in the
infected cells, the execution of apoptosis is suppressed.
This conclusion was strongly corroborated by the
ﬁndings that HRV-A16 infection counteracted the acti-
vation and execution of apoptosis upon poly I:C or pur-
omycin treatment. This notion was further supported by
western blotting for cleaved caspase-8 (Fig. 3g), and
annexin V assays (Supplementary Figure S2B−C, and S3A
−B). Remarkably, HRV-A16 not only suppressed apop-
tosis but enhanced viral necrosis, as indicated by
(see ﬁgure on previous page)
Fig. 2 Rhinovirus induces cell death without apoptotic signaling. a Electron micrographs of HeLa cells infected with HRV-A16 (MOI 1) or treated
with poly I:C or puromycin for 15 h, or uninfected cells. Proximity of vesicular structures with the cell surface indicated by black arrowheads, and
swollen mitochondrial cristae in infected cells highlighted by arrows. b Genomic DNA-laddering assay of HeLa cells infected with HRV-A16 in
comparison with puromycin-treated cells. Mr denotes relative DNA length in base pairs (bp). c ROS production of HRV-A16- or HRV-A1A (MOI 1)-
infected cells 24 h pi, compared to luprox- (100 μM, 1 h) or menadione (100 μM, 1 h)-treated HeLa cells. d Resazurin viability assay-measurement of
metabolic activity on HeLa Ohio cells after treatment with SDS, puromycin or infection with HRV-A16 (MOI 1, 10) after different time points (7, 15, 24
h). Values are means ± SD, n = 6. e FACS analysis of extracellular annexin V of HeLa cells infected with HRV-A16 or HRV-A1A (MOI 1), and comparison
with puromycin-treated cells. Values are means ± SD, n = 3. f HRV progeny formation is not inﬂuenced by pan-caspase inhibitors. TCID50 values of
cell-associated and supernatant HRV-A16 (MOI 1) of an infection kinetics from HeLa cells infected with or without pan-caspase inhibitor zVADfmk (20
μM). Values are means ± SD, n = 3. g FACS analysis of propidium iodide (PI) stainings of HeLa cells infected with HRV-A16 or HRV-A1A (MOI 1), and
comparison with puromycin-treated cells. Values are means ± SD, n = 3. h FLICA caspase-8/9 activity assays in HeLa cells infected with HRV-A16 (MOI
1) or HRV-A1A (MOI 1), and comparison with puromycin-treated cells. Values are means ± SD, n = 3. i Western blot analysis of caspase activation and
PARP cleavage in HeLa cells after infection with HRV-A16 (MOI 1, 15 h) or poly I:C treatment. Small “c” denotes cleaved protein. k Western blots
against caspase-7 (Casp7), cleaved caspase-7 (cCasp7), cleaved PARP (c-PARP), and beta-tubulin (b-Tub) from HeLa cells infected with HRV-A16 (MOI
1, 15 h), infected cells treated with pan-caspase inhibitor QVD (5 μM, 15 h), or AG7088 (rupintrivir, 20 nM, 15 h) and comparison with samples from
puromycin- and QVD-treated cells. Arrow highlights the virus-induced caspase-7 processing product.
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Fig. 3 (See legend on next page.)
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propidium iodide exclusion assays (Supplementary Fig-
ure 3C−D). Importantly, the expression of 3Cpro sup-
pressed annexin V signals induced by poly I:C, whereas
catalytically inactive 3Cpro induced apoptosis, albeit to a
lesser extent than poly I:C (Supplementary Figure S4).
These results support an important role of 3Cpro in
suppressing apoptosis. On the other hand, 3Cpro, and to a
lesser extent inactive 3Cpro induced cell lysis, as indicated
by PI assays, whereas poly I:C had no signiﬁcant effects on
PI signals. These results establish that catalytically active
3Cpro suppresses apoptosis and enhances cell lysis in
absence of other viral factors.
Caspase-independent RIPK1 cleavage by rhinovirus
RIPK1 consists of 671 amino acids, with a central p62/
SQSTM1 (sequestosome) binding domain, an RHIM-
domain, and a C-terminal death-domain (DD) (Fig. 5a).
Both RHIM and DD mediate RIPK1 binding to complexes
composed of TRIF, RIPK3, FADD, TRADD, and caspase-
846. Inspection of the RIPK1 amino acid sequence showed
that the middle p62/SQSTM1 binding domain contains
three strictly deﬁned HRV 3Cpro consensus motifs
[AVNTPISQ]-x-x-Q-[GNSA]-[PLDIQEVAN] at Q401,
464, and 57347,48. The kinase, the middle and the C-
terminal domains contain several degenerate Q-[GNSA]
motifs.
Western blot analysis of HRV-A16-infected hAECN or
HeLa cell lysates revealed efﬁcient cleavage of the 80 kDa
RIPK1 protein to 60 and 46/47 kDa proteins, both of
which reacted with an antibody recognizing the N-
terminal domain near leucine 190 (Fig. 5b, c). The 60
and 46/47 kDa proteins were prominent at 15 or 18 h pi
when progeny was produced, as indicated by the presence
of 3Cpro, VP2 and also virus titer (Fig. 5b, and data not
shown). Additional N-terminal products were observed,
including 36/37 kDa fragments, most likely processed at
degenerate 3C consensus sites (Fig. 5b, c). In support of
this notion, the 36/37 kDa fragments were not detected by
an antibody recognizing epitopes between amino acids
165 and 402, although the antibody detected the 60 and
the 46/47 kDa fragments (Fig. 5d). Neither the 60, the 46/
47 nor the 36/37 kDa bands were recognized by an anti-
body against the C-terminal amino acids 465–671 com-
prising the RHIM and the DD domains (Fig. 5d). These
results show that HRV-A16 infection generates N-
terminal RIPK1 cleavage fragments comprising the
kinase domain and variable amounts of the p62/SQSTM1
binding domain, but lacking the RHIM and DD domains.
This virus-speciﬁc RIPK1 cleavage pattern was observed
not only in HRV-A16- infected cells, but also in HRV-
A1A, B14, A2, B37 but not poly I:C-treated hAECN or
HeLa cells (Fig. 5e). Poly I:C treatment led to N-terminal
proteolytic cleavage products migrating at 35 kDa, which
were not recognized by the middle domain or the C-
terminal RIPK1 antibodies (Fig. 5d). Poly I:C treatment
further generated several C-terminal RIPK1 fragments of
45 and 40 kDa, which were not found in HRV-A16-
infected cells.
Rhinovirus 3Cpro cleaves RIPK1
We next characterized the cleavage mechanism of
RIPK1. Proteolysis of RIPK1 in puromycin-treated
apoptotic cells was suppressed by the pan-caspase inhi-
bitor QVD (as shown in Fig. 5c). Yet, treatments of HRV-
A16-infected HeLa cells with QVD, cathepsin/calpain
inhibitor E64d or RIPK1-mediated necroptosis inhibitor
NEC-149 did not affect the 60 kDa RIPK1 fragment
(Fig. 6a). Of note, NEC-1 did not affect RIPK1 cleavage
(see ﬁgure on previous page)
Fig. 3 TLR3 is required for poly I:C-induced caspase-8 activation, which can be suppressed by HRV-A16 infection, while MDA5, TRIF, and
FADD are dispensable for caspase-8 activation. a Western blots against cleaved caspase-8 (cCasp8), cleaved caspase-3 (cCasp3), VP2, 3Cpro,
MDA5, and GAPDH from lysates of HeLa cells treated with siRNA against MDA5 and infected with HRV-A16 (MOI 1, 15 h), transfected with poly I:C (5
μg/ml) or untreated samples, and comparison of protein expression after siRNA-MDA5 treatment ± pan-caspase inhibitor QVD. b Western blots
against cleaved caspase-8 (cCasp8), 3Cpro, caspase-7 (Casp7 + 3Cpro serial antibody incubation), TRIF, and beta-tubulin from lysates of HeLa cells
infected with HRV-A16 (MOI 1, 15 h), transfected with poly I:C (5 μg/ml) or untreated samples and comparison of protein expression after siRNA-TRIF
treatment ± pan-caspase inhibitor QVD; black arrow highlights virus-induced caspase-7 processing product; undeﬁned antibody background is
indicated by a star. cWestern blots against cleaved caspase-8 (cCasp8), caspase-7 (Casp7), RIPK1 (aa190), FADD, and beta-tubulin from lysates of HeLa
cells infected with HRV-A16 (MOI 1, 15 h), transfected with poly I:C (5 μg/ml) or untreated samples, and comparison of protein expression after siRNA-
FADD and siRNA-FADD/RIPK1 treatment. Black arrow highlights virus-induced caspase-7 processing product; undeﬁned antibody background is
indicated by a star. d Western blots against cleaved caspase-8 (cCasp8), cleaved caspase-3 (cCasp3), VP2, TLR3, and GAPDH from lysates of HeLa cells
infected with HRV-A16 (MOI 1, 15 h), transfected with poly I:C (5 µg/ml) or untreated, and comparison of protein expression after siRNA-TLR3
treatment with or without QVD (5 µM). Stars indicate unspeciﬁc background staining. TLR3-CT denotes C-terminal cleaved form of TLR3. e Western
blots of cleaved caspase-8 (cCasp8), VP2, and beta-tubulin from lysates of HeLa cells infected with HRV-A16 (MOI 1, 15 h), transfected with poly I:C (5
μg/ml) or untreated samples, and comparison of protein expression after siRNA-RIPK1, siRNA-TLR3 or siRNA-RIPK1/TLR3 treatment. f Knock-down of
TLR3 by RNA interference in HeLa cells, analyzed by single section confocal ﬂuorescence microscopy. Control transfections with all star siRNA are
shown on the left. TLR3 immune-staining in green, nuclei (DAPI) in blue. Scale bar 30 µm. g HRV-A16 (MOI 1, 15 h)-mediated suppression of caspase-8
activation indicated by western blots against cleaved caspase-8 (cCasp8, arrow), cleaved caspase-3 (cCasp3, p17/p20, arrow), VP2, 3C, and GAPDH
from lysates of HeLa cells after late addition of poly I:C (5 µg/ml, 6 h).
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Fig. 4 Colocalization of viral dsRNA with TLR3 and RIPK1. a Single section confocal microscopy images of uninfected HRV-A16 (MOI 1, 15 h)-
infected HeLa cells stained for TLR3 (green), dsRNA (red), and nuclei (blue). White arrowheads point to structures positive for TLR3 and dsRNA. Scale
bar 10 µm. b Tokuyasu cryo-immuno-sections of HeLa cells infected with HRV-A16 (MOI 1, 15 h); TLR3 was visualized with a rabbit TLR3 antibody and
goat anti-rabbit IgG 10 nm immuno-gold-conjugated secondary antibody (open arrowheads). dsRNA was visualized with the Mab J2 and goat anti-
mouse IgG 20 nm immuno-gold-conjugated secondary antibody (black arrowheads). Control section without immuno-gold-conjugated secondary
antibody is shown in the lower right corner. VM denotes vesicular membrane. c Serial z-stacked confocal microscopy sections of HeLa cells infected
with HRV-A16 (MOI 1, 15 h), stained for RIPK1 (green), dsRNA (red), and nuclei (DAPI, blue). Top section is 1, bottom section 6. Open arrows point to
positions of vesicular structures double-positive for RIPK1 and dsRNA. Scale bar 10 µm. d Confocal microscopy images of hAECN infected with HRV-
A16 (MOI 1, 24 h). Cells were stained for RIPK1 (green), dsRNA (red), and nuclei (blue). Single z-sections show colocalization of RIPK1 and dsRNA
puncta (white arrows).
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Fig. 5 (See legend on next page.)
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(see ﬁgure on previous page)
Fig. 5 HRV-A16 induces caspase-independent cleavage of RIPK1. a Linear representation of human RIPK1 comprising amino acids 1–671. The
kinase domain is depicted in green, the middle domain (yellow) comprising an RHIM domain (gray) is responsible for p62/SQSTM1 binding, and the
C-terminal death domain (DD, turquoise) links RIPK1 to cell death pathways. The predicted 3C consensus sequences are marked by purple lines.
Antibody binding domains are highlighted by blue lines and numbers. b Time-resolved analyses of HeLa cells infected with HRV-A16 (MOI 1) by
western blots against N-terminal RIPK1 (aa190), VP2, 3C, and GAPDH. Virus-speciﬁc RIPK1 processing products are highlighted by black arrows, and
viral precursor proteins 3CD, 3ABC, and VP0 are indicated on the right side. c Virus-speciﬁc RIPK1 processing in primary hAECN independent of
caspase. Western blots are shown against RIPK1 (leucine 190) and beta-tubulin from lysates of hAECN cells infected with HRV-A16 (MOI 1, 15 h) or
treated with puromycin (5 µg/ml, 15 h) with or without pan-caspase inhibitor QVD (5 µM). d Comparison of RIPK1 processing in infected and poly I:C-
treated cells. Western blots against N-terminal RIPK1 (leucine 190), middle domain RIPK1 (amino acids 165–402), C-terminal RIPK1 (amino acids
465–671), and beta-tubulin from lysates of HeLa cells after HRV-A16 infection (MOI 1, 15 h) or poly I:C transfection (5 µg/ml, 15 h). N-terminal virus-
induced products are highlighted by black arrows. Poly I:C-induced RIPK1 products are indicated by white arrows. Star represents an unidentiﬁed
product also present in uninfected cells. e A range of rhinoviruses including A16, A1A, B14, A2, and B37 induces cleavage of RIPK1 in hAECN and HeLa
cells. Western blots of lysates from infected (MOI 1, 15 h) or uninfected hAECN (left panel) or HeLa cells (right panel) probed with N-terminal anti-
RIPK1 antibody (L190) and anti-beta tubulin (b-Tub) antibody. Capital “M” denotes major HRV types tropic for ICAM-1, small “m” denotes minor types
tropic for LDLR and related proteins.
Fig. 6 3Cpro generates a 60 kDa N-terminal RIPK1 fragment, and supports HRV-A16 titer production late in infection. a Western blots
against RIPK1 (leucine 190), VP2, and GAPDH from lysates of HeLa cells infected with HRV-A16 (MOI 1, 15 h) and treated with pan-caspase inhibitor
QVD (5 µM, 15 h), calpain/cathepsin inhibitor E64d (10 µM, 15 h), necrostatin-1 (Nec1, 1 µM, 15 h), AG7088 (rupintrivir, 20 nM, 15 h) or drug-
combinations. The 60 kDa RIPK1 fragment is highlighted by black arrow. b In vitro cleavage of RIPK1 by 3Cpro. HeLa cell extracts were incubated with
recombinant 3C protease (r3C) with or without the 3C inhibitor AG7088 (20 nM), and analyzed by western blotting against RIPK1 (leucine 190) and
lamin A/C. Reference samples included lysates from HeLa infected with HRV-A16 (MOI 1, 15 h). RIPK1 cleavage is highlighted by black arrows. c GST-
RIPK1 cleavage in vitro. Recombinant GST-RIPK1 was incubated with r3C in presence or absence of AG7088 (20 nM) or QVD (5 µM), and reaction
products analyzed by western blotting against N-terminal RIPK1 (leucine 190), middle domain RIPK1 (amino acids 133–422), and GST. d Late addition
of AG7088 inhibits production of HRV-A16. HeLa cells were infected with HRV-A16 at three different MOI (log −1, −2, −3) and treated with AG7088 at
different times pi. The titer of viral progeny was determined from cells and supernatants 24 h pi for each time point by end point titration assays. Data
points represent mean values from three different experiments, including SD.
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or VP2 production in QVD-treated cells and HRV-A16
infection in hAECN (data not shown), conﬁrming the
earlier ﬁnding that RIPK1 per se was dispensable for
infection.
In stark contrast, the selective 3Cpro inhibitor AG7088
completely abrogated RIPK1 processing, and blocked viral
replication as indicated by the lack of VP2 (Fig. 6a). To
probe whether the 3Cpro directly cleaved RIPK1, we
incubated cell lysates with recombinant 3Cpro (r3C). This
led to the appearance of the 60 kDa N-terminal RIPK1
fragment, completely suppressed by AG7088 (Fig. 6b).
r3C did not give rise to the 36/37 and 46/47 kDa frag-
ments found in HRV-A16-infected cells, suggesting that
other viral or cellular factors generate these fragments.
This was conﬁrmed by incubation of recombinant GST-
tagged RIPK1 with r3C, which gave rise to a 90 kDa RIPK1
fragment comprising GST, the N-terminal and middle
domains of RIPK1, but no 36/37 or 46/47 kDa fragments
(Fig. 6c). Notably, appearance of the 90 kDa fragment was
inhibited by AG7088 but not by QVD. Remarkably, late
addition of AG7088 to HRV-A16-infected cells at 16 h pi
clearly reduced the production of infectious virus com-
pared to addition of the drug at 24 h pi (Fig. 6d). At 16 h
pi, the amounts of VP0 and VP2 remained constant,
implicating that 3Cpro was no longer involved in the
processing of VP0 precursor protein (see Fig. 5b). Inhi-
bition of 3Cpro by AG7088 early in infection (prior to
onset of virion production) had even stronger effects than
late addition, due to inhibition of poly-protein processing.
We conclude that 3Cpro cleaves parts of the middle
domain and the C-terminus of RIPK1, and enhances virus
replication.
Rhinovirus infection associates 3Cpro with RIPK1 and
disrupts death signaling complexes
3Cpro of A and B-type HRV (including the viruses
under study) may contain a degenerate C-terminal RHIM
domain, as deﬁned by evolutionary analyses50 (Fig. 7a).
RIPK1/3 bind to TRIF via their RHIM domains and
transmit signals to caspase-8 activation. We hypothesized
that 3Cpro interacts with RIPK1 or TRIF, and thereby
cleaves the death kinase RIPK1, and corrupts caspase-8
activation at late stages of infection.
We analyzed RIPK1 immuno-complexes of untreated,
poly I:C-treated and HRV-A16-infected cells. Immuno-
complexes with anti-procaspase-8 antibodies from
untreated cells contained full-length RIPK1 and caspase-8
proteins (Fig. 7b). In contrast, immuno-complexes of poly
I:C-activated or HRV-A16-infected cells were devoid of
full-length RIPK1. Infected cells contained a complex of
pro-caspase-8, p60 N-terminal RIPK1, and the viral 3ABC
and 3Cpro proteins. RIPK1 complexes with 3ABC and
3Cpro were conﬁrmed by immuno-precipitation with
anti-N-terminal RIPK1 antibodies (Fig. 7c). Further
analyses showed that poly I:C-induced RIPK1 fragments
were in complex with active p30 caspase-8 and also with a
p62/SQSTM1 cleavage product p45 (Fig. 7d). Notably,
HRV-A16 infection led to cleavage of p62/SQSTM1 and
gave rise to a 38 kDa product. As a consequence, binding of
full-length p62/SQSTM1 to RIPK1 was impaired (Fig. 7d).
This suggested that binding of 3ABC and 3Cpro to RIPK1-
containing immuno-complexes and proteolytic processing
of RIPK1 by 3Cpro interfered with death signaling.
TRIF complexes from both control and poly I:C-treated
cells contained full-length RIPK1, and in poly I:C-stimu-
lated cells also the proteolytic RIPK1 product p35 (Fig. 8a).
This was not observed in HRV-A16-infected cells, although
TRIF was abundantly present, akin to FADD, and the
complexes lacked full length RIPK1, p60 N-terminal RIPK1,
3ABC, and 3Cpro (not shown). Unlike RIPK1, the TRIF or
FADD immuno-complexes did not contain 3ABC or 3Cpro,
suggesting that these adaptors are dislocated from the death
signaling complex in infected cells.
In addition to C-terminal RIPK1 proteolysis, we found
that the levels of RIPK3 and the cellular inhibitor of
apoptosis protein 1 (cIAP1) were strongly reduced in
HRV-A16-infected epithelial cells 15 h pi (Fig. 8b, c).
Depletion of cIAP1 primes cells towards formation of
death receptor complex II, also referred to as the ripop-
tosome, a signaling complex containing RIPK1, RIPK3,
FADD, and caspase-8 formed upon genotoxic stress33.
Further, the depletion of RIPK3 precludes RIPK3 oligo-
merization and subsequent necrosis and necroptosis.
Unlike cIAP1 and RIPK3, BH3 interacting domain death
agonist (BID) was not proteolytically processed (Fig. 8b).
BID processing is required for activation of the mito-
chondrial and the extrinsic apoptotic pathways8. All these
results strengthen the notion that propagation of intrinsic
and extrinsic apoptosis by caspases-8/9 is impaired in
HRV-A16 infected cells.
We ﬁnally investigated the p62/SQSTM1 levels, and
found that they were strongly reduced late in HRV-A16
infection but not after poly I:C treatment (Fig. 8d). p62/
SQSTM1 is known to interact with RIPK1 and involved in
NF-κB activation, caspase-8 recruitment, and protein
turnover by autophagy51. p62/SQSTM1 depletion was
inhibited by the proteasome inhibitor MG132, or the
3Cpro inhibitor AG7088, but not NEC-1, the cathepsin B
inhibitor E64d or TNFa (Fig. 8d). NEC-1 blocks RIPK1
kinase activity and death processes, independent of cas-
pases52. Collectively, the data show that TRIF-RIPK1 and
p62/SQSTM1 containing complexes were assembled in
poly I:C-treated cells, and active p30 caspase-8 bound to
RIPK1 (Fig. 8e). Apoptotic cleavage fragments of RIPK1
remained bound to TRIF and p62/SQSTM1. Yet, in HRV-
A16 infection the RIPK1 complex was substantially
altered due to 3Cpro, and consisted of the 60 kDa RIPK1
fragment, procaspase-8, 3ABC and/or active 3Cpro and
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p62/SQSTM1. We suggest that binding of 3Cpro to
RIPK1 gives rise to a death kinase lacking death functions.
This corrupts the dsRNA-induced RIPK1-TRIF-FADD
complex without affecting TRIF and FADD expression,
suggesting that TRIF and FADD may have signaling
functions independent of RIPK1.
Discussion
A new function for 3Cpro in suppressing apoptosis and
necroptosis
How picornaviruses control cell death pathways is poorly
known. Here, we explored enterovirus interference with
apoptosis and necroptosis execution, and found that 3Cpro
controls cell death programs. 3Cpro and its precursors are
key enzymes for processing the enteroviral poly-protein.
3Cpro blocks secretion and host transcription, shuts off
protein synthesis, and interferes with nucleo-cytoplasmic
transport reviewed in refs. 20,53. 3Cpro intercepts innate sig-
naling by cleaving a variety of factors, including the TRIF54,55,
NEMO56, the complement component C357, and IPS-1
(interferon beta promoter stimulator protein 1)17. 3Cpro also
cleaves the stress granule (SG)-associated protein G3BP1,
which is essential to recruit protein kinase R (PKR) to SG, and
silences protein synthesis58.
We show that 3Cpro cleaves the death kinase RIPK1,
and precludes apoptotic and necroptotic cell death. This
has important implications, since apoptosis and necrosis/
necroptosis are well known to antagonize viral infections,
and may be involved in restricting virus spread59. Our
results show that rhinovirus-infected cells suppress the
onset of apoptosis and necrosis/necroptosis by expressing
the viral 3C protease. This is based on the ﬁnding that
3Cpro inhibition by AG7088 reduced virus progeny for-
mation and reduced PI inclusion. Furthermore, the
Fig. 7 HRV-A16 infection disrupts an RHIM domain-containing RIPK1-cCasp8-p62/SQSTM1 signaling complex, and leads to complex
formation of 60 kDa RIPK1-Caspase-8 and 3ABC/3Cpro. a Comparison of the RHIM domain from human RIPK1, RIPK3, 3Cpro from HRV-A16/B14
by sequence alignment. Yellow indicates amino acid identities, gray similarities, * denotes conserved amino acids in the RHIM domains of RIPK1/3. b
Pro-caspase-8 immuno-precipitations, and western blots against Pro-caspase-8, RIPK1 (amino acids 190) and 3Cpro from lysates of HeLa cells infected
with HRV-A16 (MOI 1, 15 h), or poly I:C (5 µg/ml)-treated cells, and uninfected samples. Input lysates and immuno-precipitations are shown. LC
denotes light chain. c RIPK1 immuno-precipitations (leucine 190) and western blot against 3Cpro from HRV-A16-infected HeLa cells (MOI 1, 15 h) or
uninfected cells. HC denotes heavy chain. d RIPK1 immuno-precipitations (leucine 190) and western blots against RIPK1, cCasp8, and p62/SQSTM1
from lysates of HeLa cells infected with HRV-A16 (MOI 1, 15 h) or transfected with poly I:C (5 µg/ml). Input lysates and immuno-precipitations are
shown. HC denotes heavy chain, IP immuno-precipitation. Arrow highlights HRV-A16-speciﬁc p62/SQSTM1 processing.
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expression of catalytically active 3Cpro per se reduced
poly I:C-induced caspase-dependent apoptosis, without
itself inducing apoptosis. It enhanced cell lysis, which may
boost virus escape from the infected cells and virus
spreading to neighboring cells60–64.
3Cpro removes the death-domain of RIPK1 and impairs
apoptosis
This alternative necrosis-like phenotype triggered by
3Cpro appears to involve double-stranded viral RNA and
cleavage of RIPK1. dsRNA-triggered apoptosis depends
Fig. 8 Interruption of RIPK1 death signaling in HRV-A16 infection. a Disruption of RIPK1-TRIF complexes shown by anti-TRIF immuno-
precipitations, and western blots against TRIF, RIPK1 (amino acids 190), and 3Cpro from lysates of HeLa cells infected with HRV-A16 (MOI 1, 15 h). Poly
I:C (5 µg/ml)-transfected control cells did not show TRIF-RIPK1 complex disruption. HC denotes heavy chain, arrow highlights co-precipitated full
length RIPK1 from poly I:C-treated cells. b Time-resolved degradation of RIPK3 but not BID. Analyses by western blots against RIPK3, BID and beta-
tubulin (b-Tub) from total lysates of HeLa cells infected with HRV-A16 (MOI 1) or transfected with poly I:C (5 μg/ml). c Time-resolved degradation of
cIAP1 in HeLa cells infected with HRV-A16 (MOI 1) analyzed by western blots against cIAP1 and GAPDH. d Western blots against p62/SQSTM1 and
beta-tubulin from lysates of untreated HeLa cells, or transfected with poly I:C (5 μg/ml), or infected with HRV-A16 (MOI 1, 24 h) ± parallel treatment
with TNFα (1 μg/ml), calpain/cathepsin inhibitor E64d (10 μM), necrostatin-1 (Nec1, 1 μM), proteasomal inhibitor MG132 (10 μM) or AG7088 (rupintrivir,
20 nM). p62/SQSTM1 expression is highlighted by black arrow. e Schematic depiction of dsRNA-induced death signaling (left) and HRV-A16
interception of death signaling (right). TLR3 senses dsRNA, which leads to formation of TRIF-RIPK1-FADD-p62/SQSTM1 complexes, recruitment, and
proteolytic activation of pro-caspase-8 to active p30 caspase-8 (cleaved Casp8) and apoptosis (poly I:C pathway, left). This may involve binding of
p30-Casp8 to RIPK1, and cleavage of an N-terminal p35 RIPK1 fragment, and p62/SQSTM1 cleavage. HRV-A16 interferes with this death signaling
pathway by 3ABC and 3Cpro binding to RIPK1, and RIPK1 cleavage to an N-terminal 60 kDa fragment. RIPK1 binds to procaspase-8, dissociates from
TRIF, FADD, and p62/SQSTM1 and interrupts apoptotic signaling. In addition, degradation of RIPK3, and processing of p62/SQSTM1 (distinct from poly
I:C triggered p62/SQSTM1 processing) further attenuate necroptotic and NF-KB signaling. This results in virus controlled necrosis.
Lötzerich et al. Cell Death and Disease  (2018) 9:272 Page 13 of 18
Ofﬁcial journal of the Cell Death Differentiation Association
on caspase-8, RIPK1, TRIF, and the RNA-sensor TLR3,
but not MDA5 and FADD. Early stages of HRV infection
showed no vast signs of apoptosis execution, indicating
that incoming viral RNA is not sensed. Late in infection,
we found that dsRNA colocalized with TLR3 and RIPK1
in vesicular structures. How dsRNA localizes into these
vesicles is unknown, but may involve virus-induced
alterations in the infected cell, or dsRNA uptake from
nearby lysed cells. Since RIPK1 coprecipitated with a
precursor of VP2 and 3Cpro, dsRNA but also viral poly-
protein may be sensed. This may initiate apoptosis, as
indicated by annexin V and FLICA caspase-8/9 stainings
15 h pi. Yet, the cleavage of RIPK1 by 3Cpro coincided
with suppression of apoptosis execution, although we
cannot exclude an involvement of 3ABC or 3CD pre-
cursors, or other viral proteases affecting alternative
RIPK1 processing. Regardless, 3Cpro coimmunoprecipi-
tated with RIPK1, and 3Cpro binding to RIPK1 and
cleaving of the RIPK1-DD correlated with the abrogation
of signaling from dsRNA-TLR3, and impaired recruit-
ment of active caspase-8, as well as activation of BID and
caspase-9. An alternative complex comprising the 60 kDa
N-terminal RIPK1 fragment, pro-caspase-8 and 3Cpro
was formed, but it lacked activated caspase-8. It is possible
that the truncated RIPK1 has intrinsic functions in
executing the necrosis-like phenotype, possibly upon
further posttranslational modiﬁcations and involving host
effector proteins. Regardless, the necrosis-like pathway
appeared to be independent of the RIPK1 kinase inhibitor
NEC-1 or the pan-caspase inhibitor QVD.
HRV-A16 infection suppresses necroptosis
dsRNA-TLR3 signaling complexes trigger necroptosis,
which involves RIPK3/RIPK1 hetero-oligomers, the cleavage
of p62/sequestosome and membrane rupture4,7,37. Our
observations of RIPK3 degradation and cleavage of RIPK1
and p62/SQSTM1 strongly suggest that HRV-A16-infected
epithelial cells suppress necroptosis. This raises the possibility
that necroptosis can function against RNA viruses, beyond
DNA viruses. Neither the RIPK1 kinase inhibitor NEC-1 nor
the depletion of RIPK1 by RNAi affected the death pathways
or HRV-A16 infection. This suggests that HRV-A16 does not
use RIPK1 to execute cell death, but cleaved RIPK1 may
affect the stability of RIPK3.
How other dsRNA sensors beyond TLR3 are controlled
in enterovirus infections remains to be investigated. Since
MDA5 and PKR pathways share adaptor proteins used in
TLR3 signaling, it is possible that the MDA5 and PKR
pathways are shut-down in HRV infection. Indeed, TLR3
and MDA5, and their adaptors TRIF and MAVS are
proteolytically processed by enteroviral and host pro-
teases19,28,29. These processes might attenuate NFκB sig-
naling, and production of pro-inﬂammatory cytokines and
type I interferon31,52. Together with the impairment of
apoptosis and necroptosis found for HRV this
indicates that enteroviruses may also be in control of cell
death processes. Our results strongly support this
notion, and indicate that the proteolytic activity of 3Cpro
leads to caspase-independent cell death with features of
necrosis.
Materials and methods
Cell lines, primary cells, and viruses
HeLa cervical carcinoma cells strain Ohio (HeLa, from
L. Kaiser; Central Laboratory of Virology, University
Hospital Geneva, Switzerland) were cultured in Dulbec-
co’s Modiﬁed Eagle Medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS) and 1% L-
glutamine. Human airway epithelial cells from nasal
biopsies (hAECN) were cultured as recommended by the
supplier (Epithelix, Geneva, Switzerland). HRV-A16 and
A1A were provided by W.M. Lee (Department of Pedia-
trics, School of Medicine and Public Health, University of
Wisconsin, USA). HRV-A2, B14, and B37 were provided
by L. Kaiser (Central Laboratory of Virology, University
Hospital Geneva, Switzerland), and CVB3 by T. Hyypia
(Department of Virology, University of Turku, Finland).
Infections were at MOI 1, as described23, unless indicated
otherwise.
Chemicals and antibodies
Poly I:C was purchased from Sigma, puromycin from
Invivogen, z-VAD-fmk from BD Pharmingen, z-LEHD-
fmk and z-IETD-fmk from Biovision, QVD-OPH and E-
64-d (loxistatin) from SM Biochemicals, TNF-alpha from
R&D systems, NEC-1 and MG132 from Tocris and
rupintrivir (AG7088) from Axon Medchem. Recombinant
RIPK1 protein and HRV3C protease were purchased from
SignalChem and Sino Biological Inc., respectively. On
TARGETplus SMARTpool siGENOME siRNAs against
RIPK1, TLR3, TICAM, FADD, MAVS, MYD88, and
MDA5 were purchased from Dharmacon. Antibodies
were obtained as follows: mouse monoclonal Mab16-7,
and rabbit polyclonal antibody detecting HRV 3C pro-
tease were kindly provided by W.M. Lee (Department of
Pediatrics, School of Medicine and Public Health, Uni-
versity of Wisconsin, USA) used as in ref. 23 and S.
Amineva (Department of Pediatrics, School of Medicine
and Public Health, University of Wisconsin, USA),
respectively. Mab J2 (English & Scientiﬁc Consulting).
Mabs against RIPK1 (C-12, aa 465–671), RIPK3 (Rippy-3),
caspase-8, beta-tubulin, and rabbit polyclonal antibody
against lamin A/C (Santa Cruz Biotechnology), Mab anti-
p62/SQSTM1 (MBL), rabbit polyclonal antibodies against
RIPK1 (D94C12, aa190), FADD, TRIF, MDA5, BID,
cleaved PARP, caspases-9, -7, -3, cleaved caspases-8, -7,
-3, GAPDH and HRP-linked secondary antibodies against
mouse or rabbit IgG (Cell Signaling), rabbit polyclonal
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antibody against GST (Sigma), rabbit polyclonal antibody
against cIAP1, TLR3 and RIPK1 (aa165–402) (Abcam),
Mab against RIPK1 (aa133–422) (Origene), and Alexa
Fluor-488 or -594 labeled secondary antibodies against
mouse or rabbit IgG (Invitrogen). Immunogold-
conjugated secondary antibodies (goat anti-mouse IgG
20 nm, goat anti-rabbit IgG 10 nm) were purchased from
BBI Solutions.
High-throughput infection of hAECN
hAECN were cultured in 96-well plates as recom-
mended by the supplier (Epithelix, Geneva, Switzerland).
At a conﬂuence of 10,000 cells/well, cells were infected
with puriﬁed HRVs or CV at different MOIs in hAECN
culture medium at 33.5 °C for 24 h, ﬁxed in 4% paraf-
ormaldehyde (PFA) and permeabilized with 0.2% Triton
X-100. Immunostaining was performed with mabJ2 anti-
body diluted in PBS containing 1% bovine serum albumin
(BSA) as described previously23. Images were acquired
with an ImageXpress Micro microscope (Molecular
Devices) in automated mode, using a CoolSNAP HQ 12
bit gray scale camera (Roper Scientiﬁc), ×10/NA 0.5
objective (Nikon) and analyzed with a custom written
script in Matlab (MathWorks, Inc. Natick, MA, USA).
Infection indexes (fraction of infected cells per total cell
number) were plotted with GraphPad Prism software
(GraphPad).
Virus titration
HeLa cells were seeded in 24-well plates, cultured
overnight at 37 °C in full medium, infected with puriﬁed
HRV-A16 (MOI1) in infection medium in presence or
absence of pan-caspase inhibitor z-VAD-fmk (20 μM). At
various time points post-infection, supernatant and
adherent cultures were collected. Cell-associated virus
from adherent cultures was released by three freeze- and
thaw steps and subjected together with cell supernatant to
titrations by serial tenfold dilutions in 96-well plates
containing nearly conﬂuent HeLa cells. Cells were incu-
bated for 4 days at 33.5 °C, ﬁxed and stained with crystal
violet. The median tissue culture infectious dose (TCID50)
was calculated according to the Spearman−Kaerber
formula.
RNA interference and virus mRNA transfection
siRNAs (20 nM, Dharmacon pools) were reverse trans-
fected to HeLa cells in 24-well or opaque 96-well plates
using serum-free Opti-MEM (Invitrogen) and Lipofecta-
mine RNAiMAX (Invitrogen) according to the manu-
facturer’s protocol. Seventy-two hours post-transfection,
cells were infected with puriﬁed HRV-A16 at MOI 1 in
infection medium (DMEM supplemented with 0.2% BSA,
1% L-glutamine and 30mM MgCl2) or alternatively with
poly I:C (5 μg/ml) at 33.5 °C for 15 h in presence or
absence of inhibitors. Cells in 96-well plates were sub-
jected to cell viability (Resazurin) assays and cells in 24-
well plates were analyzed by western blot analysis. For
entry by-pass, HeLa cells were grown in 12-well plates in
full medium at 37 °C for 24 h and transfected with viral
RNA extracted from puriﬁed HRV-A16 (TransIT-mRNA
transfection kit, Mirus Bio, USA). At different time points
post transfection cells were lysed in total lysis buffer (62.5
mM Tris, pH 6.8; 2% SDS [v/v]; 10% glycerol [v/v]; 6 M
urea; 5% b-mercaptoethanol [v/v]; 0.01% bromophenol-
blue [w/v]; 0.01% phenolred [w/v]) and subjected to
western blot analysis.
Transfection of GFP-3Cpro expression constructs
Plasmids expressing N-terminal GFP fusion constructs
of catalytically active or inactive 3Cpro were kindly pro-
vided by Reena Ghildyal (Monash University, Clayton,
Australia), described elsewhere65. Constructs were trans-
fected into HeLa cells in 12-well dishes at a density of
350,000 cells per well using Lipofectamine 3000 (Invi-
trogen) according to the manufacturer’s protocol. DMEM
medium supplemented with 10% heat-inactivated FBS
and 1% L-glutamine was replaced by serum-free Opti-
MEM (Invitrogen) 24 h post-transfection, and poly I:C (5
μg/ml) was transfected into cells using Lipfectamine
RNAiMAX (Invitrogen). Adherent cells were analyzed by
annexin V-APC/propidium iodide staining 24 h post
transfection.
Cell viability assay
In order to determine cell viability/metabolic activity,
20 μl of Resazurin solution (0.15 mg/ml in PBS, pH 7.4)
was added to siRNA-, drug-treated or infected HeLa cells
in opaque-walled 96-well plates to a ﬁnal volume of 120
μl/well and incubated for 1 h at 37 °C. Fluorescence was
recorded with a M200 Inﬁnite Plate Reader (Tecan) using
a 540 nm excitation/590 nm emission ﬁlter set. Relative
ﬂuorescence units (RFU) were plotted with GraphPad
Prism software (GraphPad).
Reactive oxygen species detection
To detect reactive oxygen species produced late during
the course of infection HeLa cells or hAECN in 96-well
plates were infected with HRV-A16 or HRV-A1A at an
MOI 1 for 15 or 24 h, respectively, and incubated for 1 h
at 37 °C with CellROX Green Reagent (Molecular Probes)
at a ﬁnal concentration of 5 μM. Cells were washed
three times with PBS and ﬁxed with 3.7% formaldehyde
in PBS. Menadione (100 μM) and Luprox (100 μM) served
as positive controls for ROS production. Fluorescence
was recorded with an M200 Inﬁnite Plate Reader (Tecan)
using a 485 nm excitation/520 nm emission ﬁlter set.
RFU were plotted with GraphPad Prism software
(GraphPad).
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Annexin/propidium iodide staining and caspase activity
assays (FLICA)
For both assays cells were cultivated in six-well plates at
a density of 5×105 cells/ well and infected the next day at
an MOI 1. At various timepoints post-infection apoptosis
or necrosis of adherent cells was determined using
annexin V-FITC (Miltenyi Biotec) and annexin V-APC
(Biolegend) kits according to the manufacturer’s instruc-
tions. Caspase-8 and 9 activities were analyzed using
carboxyﬂuorescein FLICA caspase assays (Immu-
nochemistry Technologies, LCC) according to the
instructions of the manufacturer. Puromycin (5 μg/ml)
and poly I:C (5 μg/ml) served as positive controls for
apoptosis. Fluorescence was measured within an hour
after staining by ﬂow cytometry. For each sample, 10,000
events were analyzed using an Epics Elite ESP (Beckman
Coulter), MACSQuant10 analyzer, and WinMDI 2.8 or
Flowlogic software. The fractions of positive cells were
plotted with GraphPad Prism software (GraphPad).
DNA fragmentation assay
HeLa cells in 10 cm dishes were scratched and pelleted
for 5 min at 220 g. After PBS washing the pellet was
dissolved in DNA laddering buffer (5 mM Tris, pH 7.4;
20 mM EDTA; 0.5% Triton X-100) on ice to lyse the
cells. To pellet the chromatin lysates were centrifuged at
4 °C and 10,000 g for 15 min. The supernatant contain-
ing DNA fragments was phenol/chloroform puriﬁed and
re-extracted by chloroform addition. The DNA frag-
ments containing phase was ethanol-precipitated and
ethanol-washed pellets were dissolved in DNase- and
RNase-free water (Gibco) for 30 min at RT. To remove
RNA contents RNase A (10 mg/ml, DNase free) was
added to the samples for 30 min at RT. Samples were
separated by gel electrophoresis (1.2% agarose gels
containing EtBr in TAE buffer) at 45 V for 4 h and
analyzed by UV transilluminator (G:BOX UV transillu-
minator, Syngene).
In vitro protease cleavage assays
Conﬂuent monolayers of HeLa cells were lysed in cold
RIPA buffer (50 mM Tris, pH 8.0, 150 mM sodium
chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate) for 1 h on ice, followed by
centrifugation at 10,000 g for 1 min to remove cell
debris. Lysates equivalent to 1.0×106 cells were incu-
bated with four units of recombinant HRV 3C protease
(Sino Biological Inc) at 4 °C for 16 h in presence or
absence of inhibitors. Samples were heated at 100 °C for
5 min in Laemmli buffer to stop the reaction, followed
by western blot analysis. Alternatively, 2 μg of recom-
binant RIPK1 protein in 50 mM Tris, pH 8.0, 150 mM
sodium chloride was incubated as described above with
recombinant 3C protease with or without inhibitors.
Western blots
For protein expression analysis after siRNA treatments,
poly I:C treatment or transfection, drug treatment and/ or
infection, HeLa cell or hAECN cells in 24-well plates were
washed with PBS and directly lysed in total lysis buffer
(62.5 mM Tris, pH 6.8; 2% SDS [v/v]; 10% glycerol [v/v]; 6
M urea; 5% b-mercaptoethanol [v/v]; 0.01% bromophenol-
blue [w/v]; 0.01% phenolred [w/v]) on ice. Samples were
separated by SDS-PAGE, transferred to Hybond-P PVDF
membranes (GE Healthcare) and blocked in TBS-T buffer
containing 5% milk or BSA for 1 h. Primary antibodies
were incubated overnight at 4 °C following incubation
with horseradish peroxidase-conjugated secondary anti-
bodies for 1 h at RT. Signals were detected using ECL Plus
(GE Healthcare). For immuno-precipitation analysis of
RIPK1 containing complexes untreated, HRV-A16-
infected or poly I:C-transfected HeLa cells in 10 cm
dishes were collected by scratching and washed with PBS.
1/10 of each sample was lysed in total lysis buffer. 9/10 of
the washed and pelleted sample was lysed in 150 mM NaCl
and 1% Triton-X-100 in 20mM Tris, pH 8.0, containing
protease inhibitor cocktail (Roche). Lysates were pre-
absorbed by incubation with protein A- or G-sepharose
(Amersham) at 4 °C for 1 h. To carry out coimmunopre-
cipitation speciﬁc antibody was added to the cleared lysate
overnight at 4 °C followed by protein A- or G-sepharose
incubation for 90 min at 4 °C. Samples were washed four
times with lysis buffer and once with 10mM Tris, pH 8.0
and subjected to western blot analysis as described above.
Electron microscopy
HeLa cells or hAECN on coverslips were infected with
HRV-A16 at an MOI 1, poly I:C (5 μg/ml) transfected or
puromycin (5 μg/ml) treated for 15 h. For transmission
electron microscopy cells were ﬁxed with 2% paraf-
ormaldehyde/1.5% glutaraldehyde in 0.1 M sodium caco-
dylate buffer, followed by 1% osmium tetroxide and 1%
potassium ferricyanide treatment. Aceton-dried and epon
embedded cells were cut in 90 nm slices and images were
taken using a TEM10 (Zeiss) with an Erlangshen ES 55W
model 782 camera at 80 kV. Cryo-sections of 80 nm
thickness were prepared from ﬁxed cells with an Ultracut
EM UC6/FC6 (Leica), and immunogold labeled as
described previously66,67.
Immunoﬂuorescence and confocal microscopy
HeLa cells or hAECN on coverslips were infected with
HRV-A16 at an MOI 1 for 24 h. For immunostainings,
cells were ﬁxed with 4% PFA and permeabilized with 0.2%
Triton X-100, blocked for 1 h in PBS supplemented with
1% BSA, followed by incubation with primary antibodies
in blocking buffer overnight at 4 °C. Alexa Fluor-488 or
-594 secondary antibodies were diluted in blocking buffer
for 1 h. Coverslips were mounted in mounting medium
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(Dako) and analyzed with an inverted Leica TCS
SP2 scanning laser confocal microscope with an HCX PL
APO ×63/1.4 oil immersion objective. Alternatively,
images were acquired by Leica SP8, ×63/1.40 oil (HC PL
APO CS2), zoom ×3, speed 400 Hz, line average and
resolution 4, using LAS AF software (Leica) and processed
with ImageJ (National Institutes of Health).
Statistics
The ﬁgures were assembled using Adobe Photoshop
and Illustrator. Graphs represent mean values of analyzed
samples (n) including the SD and pvalues from one-way
ANOVA with post-hoc Tukey HSD test.
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